Why daratumumab will become key for the treatment of multiple myeloma
Why has the biobank project been a success and what is the future for it?
Regis Peffault de Latour
Why we need novel strategies for diffuse large B-cell lymphoma
Updated analysis of Phase III trial of idelalisib combined with bendamustine and rituximab in CLL
Comparing ibrutinib efficacy and toxicity levels by age for patients with CLL/SLL